Table 3.
Post-VTP QoL outcome of EORTC QLQ-C30 and QLQ-PR25
| Post-treatment mean (SD) | |
|---|---|
| EORTC QLQ-C30 | |
| Global health status | 79.3 (18.1) |
| Functional scales | |
| Physical | 91.0 (16.5) |
| Role | 90.3 (19.1) |
| Emotion | 82.5 (17.9) |
| Cognitive | 91.9 (14.8) |
| Social | 87.1 (17.6) |
| Symptom scales | |
| Fatigue | 18.3 (19.1) |
| Nausea and vomiting | 1.1 (6.0) |
| Pain | 11.8 (22.8) |
| Dyspnea | 10.8 (23.4) |
| Insomnia | 21.5 (30.5) |
| Appetite loss | 6.5 (18.1) |
| Constipation | 5.4 (17.4) |
| Diarrhea | 6.5 (15.9) |
| Financial difficulties | 6.5 (20.0) |
|
| |
| EORTC QLQ-PR25 | |
| Functional scales | |
| Sexual activity (PRSAC) | 50.5 (34.6) (n = 31) |
| Sexual functioning (PRSFU) | 62.1 (17.4) (n = 20) |
| Symptom scales | |
| Urinary symptoms (PRURI) | 18.0 (16.1) |
| Urinary bother (PRAID) | 1.4 (6.5) |
| Bowel symptoms (PRBOW) | 4.5 (9.8) |
| ADT − treatment symptoms (PRHTR) | 6.1 (9.8) |
DRS, Decisional Regret Scale; VTP, vascular-targeted photodynamic therapy; QoL, quality of life; SD, standard deviation.